Berenson Oncology

Berenson Oncology is a specialized clinical research and medical practice focused on the treatment and study of multiple myeloma and related B-cell malignancies. Founded by Dr. James R. Berenson, the organization integrates private clinical practice with cutting-edge research to develop novel therapeutic strategies. They are known for conducting early-phase clinical trials and investigating innovative drug combinations, including JAK inhibitors and HDAC inhibitors. The company works closely with the non-profit Institute for Myeloma and Bone Cancer Research (IMBCR) to translate laboratory findings into clinical applications.